Hepatocellular cancer (HCC) is increasing dramatically in incidence in Europe and the United States due mainly to the hepatitis C epidemic and, to a lesser extent, increased body mass index of the population. In the fairly recent past, HCC was largely considered as untreatable due to detection mainly at late stages and lack of effective drugs for treatment. Several advances have led to changes in the prognosis of HCC. Screening of high-risk populations has allowed for earlier detection in some studies. If found at an early stage, liver transplantation not only cures the usual underlying cirrhosis but has cure rates for HCC in the range of 60% in recent series. Larger lesions can sometimes be cured by partial hepatic resection assuming the remaining liver is not too damaged to sustain liver functions after surgery. Vaccination for hepatitis B has led to reduction in the incidence of HCC. Significant improvements in antiviral treatments for both hepatitis B and hepatitis C may be having an impact on the incidence of HCC as well. It is still generally held that a finding of metastases precludes cure of HCC. We here report the case of a patient who presented with a large HCC in the context of
Long-Term Survival after Resection of Lung Metastases from

Case Report
A 62-year-old male patient presented with a large left-sided liver mass (11.3 × 9.1 × 10.5 cm, radiographically), which on biopsy proved to be a well-differentiated HCC (grade 1/4). There was portal fibrosis without bridging formation or cirrhosis in the adjacent liver (ISHAK fibrosis score 1-2/6). Liver function tests were normal at this time. The mass had a well-defined capsule which enhanced on equilibrium phase images. There was no evidence of hepatic or portal venous invasion. Several small lung nodules were seen on chest CT scan, the largest of which was 7 mm in the left lower lobe. This was removed by wedge resection and was found to have some benign changes with emphysematous and some nonnecrotizing granulomas and anthracosis. Based on this finding, it was decided to proceed with resection of the liver tumor. He then underwent a left hepatectomy which confirmed the diagnosis of HCC. Tumor was solitary, measuring 12 cm in the largest dimension, confined to the capsules with a negative resection margin (12 mm away). Tumor invasion in small vessels is also present. Tumor was staged as pT1 (however, based on the new AJCC 7th edition, tumor would be staged as pT2). There is no cirrhosis in the background liver. Approximately 13 months later, a 1.5-cm lingular nodule was noted on chest CT (enlarged from nodule seen 13 months prior in the same location). He underwent a left upper lobe wedge resection and complete lingular segmentectomy and the lingular nodule showed metastatic HCC. In the 6 years since resection of this metastasis, there has been no evidence of recurrence on CT scans of the chest, liver MRI or α-fetoprotein testing. Two years after resection of the lung metastasis, he underwent a course of pegylated interferon and ribavirin lasting 1 year and teleprevir lasting 6 months for his hepatitis genotype 1 infection. His viral load has remained undetectable since completion of therapy. The patient remains in good general health now working full time and exercising regularly. His liver function tests have remained normal. Figure 1 shows pathological findings from the primary liver resection and the lung metastasis. Figure 2 shows results of liver MRI pre-and post-resection of the primary tumor and of CT scan pre-and post-resection of the lung metastasis.
Discussion
The most frequent site of distant spread from HCC is the lungs. Most of the literature regarding resection of lung or other metastases in patients with HCC comes from Asia where there are high incidences of HCC. A recent review by Zhou et al. [1] summarized reported series of patients undergoing pulmonary metastasectomy for HCC. Some of these involved patients who developed the metastases after liver transplantation and other were in patients who had the primary cancer resected (as in our patient). The median survival in these series overall varied between 10.7 and 77 months (mean 33.2 months) and the 5-year overall survival varied from 11.5 to 75% (median 36%). Due to small numbers in most series, determination of prognostic variables has been challenging [2, 3] . Some suggested favorable features include longer disease-free interval prior to development of the metastases, low α-feto-protein level, control of the primary tumor, presence of only 1 or 2 metastases, lack of extrapulmonary metastases, and degree of tumor differentiation [1, 4, 5] . Note, however, that one series found good 2-and 3-year survivals even after resection of multiple pulmonary metastases [6] . Our case fits with many of these favorable variables including control of the primary, well-differentiated tumor, low α-fetoprotein level, a 13-month disease-free interval between the primary tumor resection and the metastasectomy, and presence of only one metastasis.
In the reported series summarized by Zhou et al. [1] , the majority of cases were associated with hepatitis B infection (~75%) as compared to ~25% of cases with hepatitis C infection. The results were not broken down according to outcomes between these two groups. Recent evidence suggests that control of hepatitis B infection improves postoperative prognosis in HCC [7] . In addition, a recent study found that lower hepatitis C viral load predicts better long-term outcome in patients who have resection of HCC [8] . Up until recently, treatment of hepatitis C infection was much more challenging than treatment of hepatitis B; however, new regimens are much better tolerated and have broader coverage of diverse strains of hepatitis C. These regimens have improved the tolerance and success of treatment greatly. Our case is of note since he had hepatitis C virus and was able to undergo effective treatment with one of the newer regimen of antivirals. Further improvements have already been made in hepatitis C virus treatment since our patient was treated. Perhaps these treatments will alter the risk HCC development or recurrence. Future studies are likely to address this question.
Our case is illustrative of improving the outlook for HCC and indicates that metastasectomy is worthy of consideration in patients with a resectable or resected primary tumor. His survival is comparable to the longest median survival reported in the literature. Our case and the recent literature appears to support a more aggressive approach to treatment of patients who have HCC and lung metastases, since outcomes are comparable to results with resection of lung metastases in colorectal cancer [9] [10] [11] . It is our impression that practitioners in the United States and Europe may be less aware of this literature. Of interest, if the initial lung biopsy had been positive in our patient, our plan was to not proceed with resection of the primary tumor. Fig. 1 . Histopathology of the primary tumor and surrounding liver and of the pulmonary metastasis. A cross-section of the primary HCC showing variegated cut surface, fibrous septae with hemorrhage and necrosis and surrounding unremarkable liver parenchyma (a); tumor is well differentiated forming trabecular and pseudoglandular patterns (b, ×100 magnification) with the presence of vascular space invasion (c, ×40 magnification). The H&E and immunohistochemical stains for pulmonary metastatic HCC show similar histopathology of the primary tumor (d, ×100 magnification), confirmed by positive stains for hepatocyte-specific antigen and glypican-3 (e and f, respectively, ×100 magnification each). 
